The authors describe the use of gabapentin in the treatment of 4 outpatients with dementia-associated agitation. On the basis of clinical case reports and the Overt Agitation Severity Scale, all 4 patients had reduced agitation with gabapentin. Most of the data to guide gabapentin use and dosing in older adults is from pharmacokinetic studies or case reports[1,2] While gabapentin is approved to prevent seizures, most patients take gabapentin for reasons of neuropathic pain (71%) or psychiatric disorders, with bipolar being most common (15%), with an average dose of 975 mg per day Cox proportional hazards regression models were used to investigate the associations between exposure to gabapentin or pregabalin and the quartiles of cDDDs of gabapentin or pregabalin exposure and the risk of dementia, adjusting other potential confounders and estimating the hazard ratios (HR) and 95% confidence intervals (CIs). We would like to show you a description here but the site won’t allow us. Our study aims to assess whether gabapentin use in chronic pain patients either increases dementia risk or offers protective benefits, using a population-based nested case-control approach. The evidence of gabapentin and dementia is mixed, with two studies looking at hundreds of thousands of people and coming to completely different conclusions. Gabapentin has been administered to several geriatric patients with bipolar disorder and patients with dementia. It has also been reported to be successful in the treatment of a 13-year-old boy with behavioural dyscontrol, a finding that suggested a possible role for gabapentin in the treatment of other behavioural disorders. Gabapentin use was significantly associated with decline in cognitive and functional status among older adults with initially normal cognition. Further studies are needed to examine the association. We present the case of a patient with incipient vascular dementia accompanied by nocturnal agitation, which was successfully treated with gabapentin. Gabapentin appears to be useful and well-tolerated in this indication. In two separate large population studies, both benzodiazepines (a category that includes medications for anxiety and sleeping pills) and anticholinergics (a group that encompasses medications for allergies and colds, depression, high blood pressure, and incontinence) were associated with an increased risk of dementia in people who used them for Objective: Previous studies have shown that gabapentin or pregabalin use is associated with cognitive decline. Herein, we aimed to evaluate the association between gabapentin or pregabalin use and the risk of dementia. Methods: In this retrospective, population-based matched cohort stu Benzodiazepines, prescribed for anxiety and insomnia, are also linked to cognitive impairment and an increased risk of dementia, especially with long-term use. Similar to gabapentin, these medications can affect neurological pathways and induce dependence, contributing to long-term brain changes. Navigating Gabapentin Use: What to Consider The adjusted odds ratio for dementia risk associated with gabapentin use was 0.91 (95 % C.I. 0.83–1.01), indicating no substantial increase in risk. Conclusion. low dose gabapentin can be used for treatment of patients with dementia with Lewy bodies. Purpose: To evaluate low dose Gabapentin (GBP) for treatment of disruptive behavioral symptoms in patients with moderate - severe dementia with Lewy bodies. Methods: A case series in a community setting. Eleven The prevalence of gabapentin use increased from 2006 to 2019, both in overall population and within every subgroup (i.e., cognitive status, age group, and sex). About 10–30% of gabapentin users reported to concurrently use gabapentin with opioids. Over one-half of gabapentin users with dementia concurrently used gabapentin with antidepressants. The first case report published about the use of gabapentin in agitation in dementia was by Regan and Gordon 50. In this case, the average dose used was 600 mg day −1. The patient, a woman aged 68 with Alzheimer's dementia (AD) had less agitation as per nursing observational reports after 12 weeks of treatment. Some research indicates that Gabapentin may have an impact on cognitive function, particularly in older adults. Here are some key findings: **Cognitive Decline**: A study published in the Journal of Alzheimer’s Disease found that long-term use of Gabapentin was associated with a decline in cognitive function in older patients. The HR (95% CI) of dementia for gabapentin or pregabalin exposure was 1.45 (1.36–1.55) compared to non-exposure group, after adjustment for diabetes mellitus, hypertension, stroke, hyperlipidemia, depression, and head injury. The adjusted odds ratio for dementia risk associated with gabapentin use was 0.91 (95 % C.I. 0.83-1.01), indicating no substantial increase in risk. Conclusion: Long-term Gabapentin therapy for chronic pain is not associated with a differential risk of dementia across dosage levels, irrespective of age or gender. Especially in older adults, gabapentin is prescribed to treat behavioral and psychological symptoms of dementia (BPSD) (Kim et al., 2008). Several studies have reported that gabapentin has a deleterious effect on cognition (Leach et al., 1997; Meador et al., 1999; Shem et al., 2018).
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |